Reserpine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Reserpine
Reserpine: Known uses and market status in India
Summary
The TxGNN deep-learning model produced candidates for Reserpine with a score of 0.99 or higher. Every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for Reserpine.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 0 |
| Evidence level | Not applicable |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
India Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 5857 | Adelphane 0.1mg/10mg Tablet | strip of 10 tablets | Valid |
Safety Considerations
- Contraindications flagged in the knowledge graph (these are model-derived associations, not package insert text):
- Liver: liver failure, liver disease, cirrhosis, hepatic coma, hepatic encephalopathy
- Kidney: kidney disease, anuria, nephrocalcinosis, pyoureter
- Gastrointestinal: peptic ulcer disease, pancreatitis, gallbladder disease
- Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, gout, hyperuricemia, hypercalcemia, hyperparathyroidism, potassium deficiency, phosphorus metabolism disease
- Neuropsychiatric: epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder
- Other: hypotensive disorder, systemic lupus erythematosus, neonatal jaundice, slow acetylation
- Drug Interactions: 103 interactions were recorded. The 20 listed in the data were all of Moderate severity:
- Corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide
- Antidiabetic agents: canagliflozin, dapagliflozin, empagliflozin, chlorpropamide, glimepiride, repaglinide, insulin aspart, degludec, detemir and glargine
- Sympathomimetics and stimulants: epinephrine, bupropion, diethylpropion, phentermine
- Other: dronabinol
The concern about depression and dysthymic disorder is especially relevant for a psychiatric population.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.